Session » SLE – Diagnosis, Manifestations, & Outcomes Poster I

Date: Saturday, November 16, 2024

Time: 10:30AM-12:30PM

Meeting: ACR Convergence 2024

10:30AM-12:30PM: Abstract Number: 0640

7000-Plex Proteomic Screen of Urine for Flare Monitoring and Treatment Response Biomarkers in Active Lupus Nephritis

10:30AM-12:30PM: Abstract Number: 0637

Active Implementation of Low Disease Activity State as Treatment Endpoint in a Large Cohort of Adolescents and Young Adults with Childhood Onset Systemic Lupus Erythematosus

10:30AM-12:30PM: Abstract Number: 0652

Analysis of Relapses in a Single Center Cohort of Patients with Lupus Nephritis

10:30AM-12:30PM: Abstract Number: 0642

Anti-Myxovirus Resistance Protein 1: A Novel Biomarker for Autoimmune Myositis and Interstitial Lung Disease in Systemic Lupus Erythematosus

10:30AM-12:30PM: Abstract Number: 0614

Bridging the Gap Between Patient’s Perception on Quality of Life and Disease Activity and Damage in Systemic Lupus Erythematous Patient

10:30AM-12:30PM: Abstract Number: 0646

Chart Audit of over 1,000 SLE Patients Reveals Biologic Treatment Choice Driven by Disease Manifestations

10:30AM-12:30PM: Abstract Number: 0647

Clinical Associations and Outcomes of Pericarditis in Systemic Lupus Erythematosus

10:30AM-12:30PM: Abstract Number: 0627

Clinical Conditions Associated with Presence of a High-titer Antinuclear Antibody in Individuals Without Autoimmune Disease

10:30AM-12:30PM: Abstract Number: 0620

Clinical Efficacy and Patient-Reported Outcomes in Anti-Ro/Sjögren’s Syndrome–Related Antigen a Antibody–Positive Patients with Active SLE Treated WithDeucravacitinib in the Phase 2 PAISLEY Trial

10:30AM-12:30PM: Abstract Number: 0610

Clinical Evaluation on IFI44L Gene Methylation Detection for Diagnosis of Systemic Lupus Erythematosus by Methylation Sensitive High Resolution Melting (MS-HRM)

10:30AM-12:30PM: Abstract Number: 0634

Clinical Relevance of the Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) in Predicting Lupus Outcomes: A 5-Year Longitudinal Cohort Study

10:30AM-12:30PM: Abstract Number: 0624

Coexisting Tubulointerstitial Inflammation and Damage Is a Risk Factor for Chronic Kidney Disease in Patients with Lupus Nephritis

10:30AM-12:30PM: Abstract Number: 0618

Comparison of Cell Type-Specific Polygenic Risk in Systemic Lupus Erythematosus Patient and Healthy Controls

10:30AM-12:30PM: Abstract Number: 0654

Corneal Confocal Microscopy: An Ophthalmic Imaging Biomarker for Small Fiber Neuropathy in Systemic Lupus Erythematosus

10:30AM-12:30PM: Abstract Number: 0632

Cutaneous Lupus Erythema and Scale Have Similar Six-month Trends Without Significant Impact from Race/ethnicity or Disease Subtype

10:30AM-12:30PM: Abstract Number: 0657

Data-driven Bayesian Network Analysis for Predicting Difficult-to-treat (DTT) Lupus Nephritis

10:30AM-12:30PM: Abstract Number: 0639

Delayed Diagnosis in Systemic Lupus Erythematosus

10:30AM-12:30PM: Abstract Number: 0616

Disparities in Health-Related Quality of Life Among Patients with Systemic Lupus Erythematosus

10:30AM-12:30PM: Abstract Number: 0629

Evaluating the Concordance Between SRI4 and BICLA Using Placebo Data from Randomized Controlled Trials of Patients with Active Systemic Lupus Erythematosus

10:30AM-12:30PM: Abstract Number: 0636

Evaluation of Clinical, Histological and Biomarker Response After Induction Treatment of Lupus Nephritis (LN)

10:30AM-12:30PM: Abstract Number: 0628

Genetic Determinants of Childhood Onset Systemic Lupus Erythematosus

10:30AM-12:30PM: Abstract Number: 0617

Hereditary C1q Deficiency Is Associated with Type 1 Interferon-pathway Activation and a High Risk of Central Nervous System Inflammation

10:30AM-12:30PM: Abstract Number: 0631

Impact of Baseline Proteinuria Level on Long-term Outcomes in Lupus Nephritis

10:30AM-12:30PM: Abstract Number: 0653

Impact of Lupus Nephritis on Neuropsychiatric SLE Outcomes

10:30AM-12:30PM: Abstract Number: 0626

Impact of the Lupus Foundation of America Rapid Evaluation of Activity in Lupus (LFA-REAL) Patient Reported Outcome (PRO) in Systemic Lupus Erythematosus Patients from the Almenara Lupus Cohort

10:30AM-12:30PM: Abstract Number: 0630

Lupus Lymphocyte Activation Score of Pathologic T and B Cell Phenotypes Increased in Patients at Risk of Systemic Lupus Erythematosus

10:30AM-12:30PM: Abstract Number: 0656

Lupus Myocarditis: Clinical Characteristics, Cardiac Magnetic Resonance Imaging Findings and Outcomes

10:30AM-12:30PM: Abstract Number: 0635

Medical Record Natural Language Processing and Patient Biometric and Self-Reported Measures Inform an Artificial Intelligence Augmented Remote Care Management Strategy for Lupus Patients

10:30AM-12:30PM: Abstract Number: 0645

Mortality and Ethnicity in Adults with Systemic Lupus Erythematosus: A Systematic Literature Review and Meta-Analysis

10:30AM-12:30PM: Abstract Number: 0633

Novel LINE-1 Reverse Transcriptase Inhibitors Can Suppress Type I Interferon Responses and Are Promising Therapeutics for Lupus

10:30AM-12:30PM: Abstract Number: 0612

Performance of the Systemic Lupus Erythematosus Risk Probability Index (SLERPI): Results from the Egyptian College of Rheumatology (ECR) Study Cohort

10:30AM-12:30PM: Abstract Number: 0607

Plasma Proteomic Analysis Reveals Type I Interferon Blockade Effects of Anifrolumab in Lupus Nephritis: Insights from a Phase 2 Trial

10:30AM-12:30PM: Abstract Number: 0613

Prediction of Spontaneous Abortion in Women with Systemic Lupus Erythematosus (SLE) Based on Machine Learning Model: Insights from the Egyptian College of Rheumatology (ECR)–SLE Cohort

10:30AM-12:30PM: Abstract Number: 0621

Predictive Parameters of Disease-related Damage Accrual in Patients with Systemic Lupus Erythematosus: A Machine Learning Analysis

10:30AM-12:30PM: Abstract Number: 0641

Predictive Validity of Coronary Artery Calcium Scoring in Low Risk Systemic Lupus Erythematous Patients

10:30AM-12:30PM: Abstract Number: 0619

Prevalence and Factors Predicting Hemophagocytic Lymphohistiocytosis in Hospitalized Patients with Systemic Lupus Erythematosus

10:30AM-12:30PM: Abstract Number: 0648

Prevalence of Pulmonary Complications Among Patients with Systemic Lupus Erythematosus (SLE): A Systematic Review and Meta-analysis

10:30AM-12:30PM: Abstract Number: 0655

Relationship Between Patient-Reported Outcomes to Hospitalization in Patients Living with SLE: A Retrospective Cohort Study Utilizing the FORWARD Lupus Registry

10:30AM-12:30PM: Abstract Number: 0651

Renal Survival and Mortality in Patients with Proliferative and Membranous Lupus Nephritis

10:30AM-12:30PM: Abstract Number: 0644

Scoping Literature Review to Identify Candidate Domains for the SLE OMERACT Core Outcome Set

10:30AM-12:30PM: Abstract Number: 0623

Select Patient Reported Outcome Measure Domains Enhance Immune Mediator Based Indexes That Inform Flare Risk and Disease Activity in Systemic Lupus Erythematosus

10:30AM-12:30PM: Abstract Number: 0615

Socioeconomic Determinants of Lupus Hospitalization Outcomes: A Review of Current Knowledge and Analysis of the 2016-2019 NRD Database

10:30AM-12:30PM: Abstract Number: 0638

Soluble TNF RII in Lupus Nephritis as a Biomarker of Disease Activity and Treatment Response

10:30AM-12:30PM: Abstract Number: 0611

Subclinical Atherosclerosis Is Associated with Future Cardiovascular Events in Systemic Lupus Erythematosus Patients at Apparent Low Risk for Cardiovascular Disease: A Longitudinal Prospective Study

10:30AM-12:30PM: Abstract Number: 0608

Systematic Analysis Demonstrates the Added Value of CB-CAPs to SLE Diagnosis in a Large Validation Cohort

10:30AM-12:30PM: Abstract Number: 0609

The Mediating Role of Trust in Usual Rheumatologists on the Relationship Between Multidimensional Health Literacy and Medication Adherence Among Japanese Systemic Lupus Erythematosus Patients

10:30AM-12:30PM: Abstract Number: 0622

Translation, Adaptation and Validation of the Brazilian-Portuguese Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) Version: Partial Results from a Single Centre

10:30AM-12:30PM: Abstract Number: 0625

Trends, Outcomes, and Predictors of Mortality in Patients with SLE Hospitalized for Influenza

10:30AM-12:30PM: Abstract Number: 0650

Tubulointerstitial Inflammation Predicts Tubular Atrophy, Fibrosis, and Renal Function Loss in Lupus Nephritis

10:30AM-12:30PM: Abstract Number: 0649

Urinary Acetylated Albumin as a Biomarker of Nephritis in Patients with Systemic Lupus Erythematosus

10:30AM-12:30PM: Abstract Number: 0643

Using FDG PET Brain Scans and Deep Learning Analyses to Identify a Specific Network Correlated with Cognitive Impairment in SLE

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].